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Every 5 minutes someone in America dies of an overdose. The single greatest barrier to increasing naloxone access is FDA’s designation of naloxone as prescription-only. For the first time, we highlight how 
prescription-only status cascades into myriad unexpected legal and 
practical barriers. We ask Congress and FDA to remove generic naloxone’s 
prescription requirement for Harm Reduction programs, so that we may 
prevent overdose deaths more effectively and affordably.

Remedy Alliance (For The People) operates the Opioid Safety and Naloxone Network 
(OSNN) Buyers Club, established in 2012. The Buyers Club is a collective of over 100 
harm reduction programs who distribute naloxone directly to people who use drugs, their 
loved ones and community. Remedy Alliance is a non-profit organization.
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Naloxone kits in an outreach bag, ready to hit the streets.
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Summary 
This month the US will surpass a once-unimaginable milestone: over 100,000 
people dead from overdose in the past year. Over 70% of these deaths are 
caused by opioids and many of them are preventable with the rapid 
administration of naloxone. Community-based naloxone distribution is a 
rigorously evaluated, evidence-based intervention.

States have done everything they can to increase naloxone access, passing laws 
and executive orders to greatly simplify prescribing and distribution. FDA has 
clearly signaled their willingness to consider over-the-counter status for naloxone. 
However, significant legal barriers to purchasing of naloxone by community-based 
programs stem from FDA’s continued designation of naloxone as “prescription-
only.”

As long as generic naloxone remains prescription-only at the federal level, 
corporate and local government compliance officers will adhere to the most risk-
averse position, even if that contravenes State legislative intent. We have been 
told “No” at every level of the supply chain. The reason is always: “Naloxone is a 
prescription drug.”

We provide 7 specific examples across every level of the supply chain. The 
Cascade of Consequences severely curtails naloxone expansion and public 
health innovation.

We recognize that FDA does not factor cost when considering regulatory 
decisions. However for naloxone, cost, availability, and lives saved are intimately 
linked. When $2.50 generic naloxone cannot be purchased because of fear of 
FDA enforcement, public funds are spent on a $75 branded version. That equates 
to 30-fold fewer naloxone kits distributed.

The discrepancy between state medical/pharmacy practice vs. federal interstate 
commerce regulation, requires urgent resolution and forms the basis for 
immediate Congressional intervention. We are ready to work with FDA and 
Congress to eliminate the Cascade of Consequences stemming from naloxone’s 
prescription-only status. We share the sincere goal of reducing overdose deaths 
immediately. We have faith that the federal government will respond favorably to 
this new information about barriers to naloxone access.
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Policy Landscape 
In April 2021, the Biden Administration stated it will: “Examine naloxone 
availability in counties with high rates of overdose and identify opportunities to 
expand access in targeted areas among pharmacies, clinicians, peer support 
workers, family and community members, and PWUD.” (source) In this document 
we provide previously undisclosed information to aid the Administration in finding 
solutions to the overdose death epidemic.
We invite FDA to work with us, and the US Senators we have already engaged, to clear the 
single largest barrier to wider naloxone access: prescription-only status. 
Harm Reduction programs are our first line of defense to preventing overdose 
deaths. They are adept at reaching marginalizied communities that mainstream 
medicine and public health cannot. They have distributed naloxone that laypeople 
have used to reverse hundreds of thousands of overdoses. Unfortunately, their 
ability to quickly and effectively get naloxone to the people who are most likely to 
reverse overdoses continues to be hampered by legal and regulatory barriers. 
These barriers slow down, and sometimes prevent entirely, purchases of 
naloxone. Even though purchasers have money and vendors have product, public 
health programs find FDA’s prescription-only designation a fatal impediment. 

State legislatures and health departments have clearly expressed intent that 
naloxone be deregulated and treated as OTC under their authority over medical 
and pharmacy practice. All 50 states, DC and Puerto Rico have done what they 
can, passing laws and issuing executive medical orders enabling naloxone to be 
sold and/or distributed without a prescription. (source)

Similarly, FDA has clearly stated its intent to consider OTC naloxone, through 
statements and publications by the current and previous three Commissioners. 
FDA convened Public Workshops on April 2012 and July 2015, and an Advisory 
Committee Meeting in December 2018, where we described the need for OTC 
naloxone in detail. Unfortunately, FDA has not taken the next logical stop: Moving 
one or more formulations of the medication OTC.
While state laws and orders intend for naloxone to be treated as OTC, it remains 
regulated as prescription-only at the federal level, affecting interstate commerce. 
This discrepancy limits the ability of many organizations to obtain and distribute 
it. As illustrated in the following examples, the incongruity manifests as resistance 
from corporate and government compliance officers.
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Cascade of Consequences
We provide 7 examples of structural barriers preventing naloxone access 
precipitated by prescription-only status. We can provide 993 more. While each 
problem is solvable in isolation, the collective impact is deadly.

1. Large pharmaceutical manufacturer
For Harm Reduction programs, Pfizer requires DEA registration of the prescribing 
physician even though naloxone is not a controlled substance. In their ordering 
system, one prescribing physician cannot provide their DEA authorization to 
multiple Harm Reduction programs, thus rendering statewide standing orders 
useless for naloxone procurement. Prescription-only status forces highly 
restrictive corporate compliance interpretations.

2. Small, generic pharmaceutical manufacturer
Hikma Pharmaceuticals (previously West-Ward) requires physicians working with 
Harm Reduction programs to sign affidavits clarifying that their naloxone 
prescription explicitly authorizes “purchase,” and not solely “distribution.” 
Corporate compliance officers require this burdensome paperwork to document 
the transaction out of fear of FDA enforcement. This applies even to states with 
standing orders, some of which explicitly forbid purchasing. Prescription-only 




Distributors do not have a model for situations of state-OTC versus federal-Rx. 
For example, a convoluted fix was necessitated by the fact that the prescription 
product division (McKesson Pharma) is a separate commercial entity from the 
medical supplies division (McKesson MedSurg), and syringe service programs are 
ineligible for McKesson Pharma accounts because they are not pharmacies. 
Therefore, naloxone has to be transferred between these divisions, creating 
delays and additional supply chain vulnerabilities. McKesson sales reps are often 
uninformed about this arrangement, resulting in idiosyncratic order quotes or 




As one corporate official put it: 
“If FDA had intended for naloxone to be easy to get,  
they would have made it OTC by now." 
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4. Regional Public Health Organization 
The Northwest Portland Area Indian Health Board serves 43 tribes in Washington, 
Oregon and Idaho. These rural and remote Native American communities have 
limited emergency medical care, and most have no access to in-person Harm 
Reduction. While the organization can purchase naloxone, a legal assessment has 
prohibited them from mailing naloxone across state lines because the status is 
prescription-only. Fear of FDA action limits the lifesaving antidote from 
reaching rural Native American communities.  
Source: Jessica Leston, Clinical Programs Director, NPAIHB 
5. Local Public Health Program 
A public health initiative in Michigan purchased 15 vending machines to place 
free naloxone 24/7 in high overdose and service-scarce areas. Despite an 
enabling state standing order, the fear of federal enforcement by FDA killed many 
target locations. Lawyers and organizational general counsels stalled 
implementation because naloxone is prescription-only and several vending 
machines continue to sit in a storage room. The same is situation is occurring in 
Connecticut. Fear of FDA enforcement of prescription-only status stifles 
overdose prevention innovation.

6. Charitable Donations of Naloxone
In order to receive a charitable donation of no-cost naloxone, programs must 
meet compliance requirements dictated by prescription-only status. To receive 
free naloxone through Direct Relief (Pfizer’s donation of 1 million doses), 
programs must: “comply with State Board of Pharmacy regulations in storing and 
dispensing medications; and have a Medical Director or Pharmacist with a valid 
state license.” Recently, the Buyers Club received a separate commitment of a 
50,000 dose donation for member programs, and only three programs were able 
to produce the required paperwork to receive an emergency donation. Even 
when cost is not an issue, regulatory and compliance issues continually 
leave overdose prevention efforts stymied. 

7. Individual Level
Of the many tragic stories we have heard about the lack of naloxone access, 
perhaps most heartwrenching is that of Jack Fishman, who invented naloxone in 
1961. His stepson died of a heroin overdose in Florida. Joy Stampler, Jack’s wife 
at the time, said: “It was hard for Jack to get naloxone even though he invented 
it!" (source) Prescription-only status leads to thousands of avoidable deaths.
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Naloxone Market 
Despite the barriers, the Buyers Club accounts for a large proportion of all 
community-based distribution in the entire country. Recent modeling has 
suggested that no state is giving out enough naloxone in the community. 

(There has been a dearth of public information on naloxone distribution channels, 
with higher volumes in recent years.)
• Buyers Club: 1.3 million doses in 2020, 4 million doses 2017 through 2020, 
entirely injectable, cheap, generic naloxone. (source)
• Veterans Administration: 200,000 doses from May 2014 to September 2019 
(source), or 31,000 doses per year.
• Retail Pharmacy: 336,100 doses in 2017 (source) and 556,847 in 2018 (source), 
including intranasal.
• Pfizer donation to Direct Relief: 1 million doses over four years, 2017 to 2021.
(source)

• In 3Q2018 Emergent BioSolutions reported sales of <250,000 doses per quarter 
(source, slide 4), now surely million+ per year. However, this includes extensive 
sales to law enforcement and other venues with considerably lower naloxone 
utilization rates per unit dispensed.

• The largest state-based effort, by the California Department of Health Care 
Services, purchased 600,000 units of naloxone from 2018 to 2021 on behalf of 
programs, funded by SAMHSA. (source) But this volume was so inadequate 
that programs purchased tens of thousands of additional doses through the 
Buyers Club. Cheap, generic naloxone via the Buyers Club is a backstop for 
inadequate federal funding.
• The global naloxone nasal spray market is estimated to be $351 million in 2021. 
(source) In contrast, if we tripled (3x) community-based distribution of generic 
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On-the-ground Reality Check 
October 2021, Denver, Colorado 
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Naloxone Pricing 
Compared to the nasal sprays, naloxone purchased through the Buyers Club 
is 30x cheaper. 
Intramuscular naloxone is the most cost efficient option for community-based 
programs. During 25 years of community-based distribution, the intramuscular 
naloxone formulation is considered highly acceptable among people who use 
drugs in syringe service programs.

In the graph below, naloxone costs assume 2.5 doses of intramuscular naloxone 
per kit, and 2 doses for nasal spray. These costs do not include distribution labor, 






Source: The Guardian, October 2021 and Filter Magazine, April 2021
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Federal Financial Support for Naloxone  
53% of Buyers Club programs receive no federal funds for naloxone. 
Internal data from 2020 OSNN Buyers Club survey, n=70 programs responded.

Other Findings 
• Half of Buyers Club programs report having to do fundraising to purchase 
naloxone. GoFundMe pages, t-shirt sales, and donations to overdose memorial 
funds are common.

• A quarter of programs (25.3%) report regularly rationing naloxone due to 
inadequate financial support from state and federal government.







The backbone of naloxone distribution in the United States teeters on 
donations and volunteer time. With 100,000 overdose deaths each year,  
it’s time to finally recognize the truth. 
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Retail Pharmacy: Marketing vs. Reality 
The majority of community-based naloxone distribution to people who use drugs 
is hand-to-hand. It occurs far from retail pharmacy shelves. Yet, the main branded 
manufacturer (Emergent BioSolutions) has forwarded a narrative emphasizing 
retail pharmacy as the sole avenue for OTC, based on their expensive nasal 
spray; they have not extended an alternate price that Harm Reduction programs 
can afford. An FDA analysis suggests that retail pharmacy sales of naloxone are 
highly concentrated in a handful of states. During COVID, retail pharmacy sales of 
naloxone declined 26%, while demand from Buyers Club programs increased 
29%.

The truth is that injectable naloxone has been used successfully by people who 
use drugs since 1996. Research shows that people who use drugs are best-
placed to reverse overdoses as they happen. (source) People who use drugs do 
not feel comfortable purchasing naloxone in pharmacies (source). It is imperative 
that we find ways to to get lifesaving medication into the right hands.

Our experience and research from the United States, Vietnam, and Norway has 
shown that “Super-savers” naturally and consistently emerge during naloxone 
distribution. (source) These empowered and motivated individuals report 
reversing multiple overdoses, having gained a positive reputation. In one study, 
the “Super-saver” group made up 15% of the sample but contributed to 29% of 
take-home naloxone use. (source)

Exclusive focus on retail pharmacy for OTC naloxone disadvantages those 
who are most likely to save lives.  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Source: FDA Briefing Document, 2018
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Targeted Action
We request that FDA remove the prescription-only designation for generic 
naloxone. A narrower ask could be limited to syringe service and Harm Reduction 
programs. Since OTC status for all naloxone products is likely not acceptable to 
the Agency, we have come up with a game changer solution: A new, exclusive 
naloxone product, within an established restricted-access program. We have 
reached a contractual agreement with an existing manufacturer to create an 
exclusive 0.4 mg (in 1 mL vial) product (already approved), with a new NDC, for 
$2 per vial. The Pfizer version could also be included. The existing Buyers Club 
access control program vets each member, ensuring that they are nonprofits 
serving a population comfortable using needles. FDA has new authority under the 
2020 CARES Act to initiate OTC switches, through the OTC Monograph Reform 
Process. Thus far the agency has prioritized wart removers, ingrown toenail 
treatments, and anti-flatulent medications.

Waiting for a generic company to initiate an OTC switch for naloxone is 
tantamount to granting exclusive access to the OTC process to branded 
companies with more expensive products. FDA’s decade-long exclusive 
endorsement of expensive branded nasal and auto-injector formulations has set 
an insurmountable precedent that no generic manufacturer we have spoken to is 
willing to challenge.

To our knowledge, FDA has not taken enforcement action against regulated 
industry or local programs around naloxone. Nor has FDA formally stated its 
intention to exercise enforcement discretion. The silence has a chilling effect.

Legislative Intervention 
We will continue to pursue Congressional intervention. On October 20, 2021, 
Senators Tammy Baldwin (WI) and Tina Smith (MN) called for HHS action to 
increase intramuscular naloxone availability. Senators Bernie Sanders (VT) and 
Elizabeth Warren (MA) have proposed invoking Section 1498 Defense Production 
Act powers to compel a supply of affordable naloxone for Harm Reduction 
programs. (source) In additional conversations with some of these offices and 
those of Senators Cory Booker (NJ) and Angus King (ME), the question has not 
been if, but rather how, to move FDA to eliminate prescription status for Harm 
Reduction programs. If FDA is unwilling to act immediately, Congress could act to 
remove the prescription requirement for all naloxone products, or only the 
restricted-access version(s). 
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